Press Releases

Cellistic Launches Echo™ – NK Platform, a Scalable Solution for Off-the-Shelf Allogeneic Immune Cell

News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies. The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases. It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.

ELRIG Appoints Dr Del Trezise as Chair

Phenomix Sciences Announces First Prospective Clinical Study of Semaglutide Using MyPhenome™ Test

Building on a decade of research and validation, study leverages precision, phenotype-guided treatment for enhanced patient outcomes on GLP-1s.

CDMO Upperton Continues Growth with the Appointment of Michael Mellor-Clark as Chief Commercial Officer.

Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), continues its growth following the build of a new sterile manufacturing facility with the appointment of Michael Mellor-Clark as Chief Commercial Officer (CCO).

Indivumed Celebrates Milestone of Its Patient-Centric R&D Platform: Numerous Novel Cancer Targets Discovered for First-in-Class Therapeutics

Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company.

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company’s growth and vision to help bring certainty and transparency to global clinical trials

AES Cleanroom Technology introduces Omni ASCENT: a breakthrough in cleanroom utility integration at INTERPHEX 2025

ONTOFORCE’s DISQOVER Chosen by The Michael J. Fox Foundation to Enhance the Integration and Access of Parkinson’s Disease Research Data

ONTOFORCE has announced a collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

WCG Announces Research Resilience Solutions to Navigate Institutional Budget Constraints

WCG has announced the release of Research Resilience Solutions, a site optimization initiative and industry-wide thought leadership series aimed at supporting institutions facing significant funding constraints.

Veeva Announces Research Site Clinical Trial Management System

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsors.

Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

CluePoints Appoints Usama Dar as Chief Product and Technology Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has today announced Usama Dar as its new Chief Product and Technology Officer.

Genomize and Genomenon Partner to Empower Researchers and Clinicians with Comprehensive Genomic Insights

Genomenon and Genomize today announced a new partnership that brings together the best of genomic intelligence and next-generation sequencing technology to transform how genomic data is interpreted. Through this integration, Genomenon’s Mastermind® Genomic Intelligence Platform and Cancer Knowledgebase (CKB) are now seamlessly embedded within Genomize’s SEQ Platform, enabling a unified and deeply enriched analysis environment. This partnership marks a major step forward in streamlining genomic analysis and advancing precision medicine—especially across Europe, the Middle East, and Asia, where Genomize is actively leading innovation.

WCG ClinSphere™ Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection

WCG announced today the launch of WCG ClinSphere™ Total Feasibility’s Software-as-a-Service (SaaS) technology solution, designed to address the most important clinical trial study start-up decisions for sponsors and contract research organizations (CROs).

Inizio Medical Launches iON.AI to Transform Medical Affairs Capabilities

Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.

PwC certifies KELES as first VC-firm to achieve SFDR Article 9 for digital health investment

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form category.

Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO Leadership Awards.

Femasys Gains European Approval for FemBloc Delivery System, Advancing the First Non-Surgical Option for Permanent Birth Control

European women will soon be able to receive permanent birth control through a non-surgical approach. FemBloc, developed by Femasys, a leading biomedical innovator addressing significant unmet needs in women's health worldwide, announces Conformité Européene (CE) mark certification under the European Union Medical Device Regulation (EU MDR) as the first regulatory approval in the world for the FemBloc® delivery system for non-surgical female permanent birth control.